Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advised Hemfosa Fastigheter AB in connection with the acquisition of the Landic VIII portfolio
Mandate

Vinge advised Hemfosa Fastigheter AB in connection with the acquisition of the Landic VIII portfolio

February 03, 2011

Vinge has advised Hemfosa Fastigheter AB in connection with the acquisition of the Landic VIII portfolio for approximately SEK 2.2 billion. The portfolio consists of 57 properties spread over 42 locations in Sweden. Almost 80 per cent of the rental income emanates from public authorities. Several of the properties have a market value of between SEK 5-40 million, although the portfolio also includes large properties such as the premises occupied by the Swedish Migration Board in Norrköping (Presidenten 1), the municipal council building in Haninge (Söderbymalm 3:486) and Sollentuna police station (Transporten 2). The portfolio comprises a total of 300,000 sq. m. and most of the lettable area consists of office space.

Vinge’s team consisted of partner Patrick Forslund and associates Niclas Winnberg and Daniel Unger.

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

 Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

 Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025